help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Golden, R. N.
Right arrow Articles by Potter, W. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Golden, R. N.
Right arrow Articles by Potter, W. Z.

Journal of Clinical Endocrinology & Metabolism, Vol 68, 632-637, Copyright © 1989 by Endocrine Society

ARTICLES

The effects of intravenous clomipramine on neurohormones in normal subjects

RN Golden, J Hsiao, E Lane, R Hicks, S Rogers and WZ Potter
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599.

The neuroendocrine effects of iv administration of clomipramine (CMI), a serotonin reuptake inhibitor, were studied in normal subjects. Under double blind, placebo-controlled conditions, single 10- and 20-mg doses of CMI were administered. Ten milligrams of CMI led to significant increases in plasma PRL and cortisol concentrations; plasma ACTH increased slightly but not significantly. In contrast, plasma GH, melatonin, and norepinephrine concentrations did not increase. Plasma PRL, ACTH, and cortisol levels increased significantly after 20 mg CMI; again, there were no significant changes in plasma GH, melatonin, or norepinephrine concentrations. All subjects tolerated the 10-mg dose well, but the 20-mg dose caused nausea in three of six subjects. Desmethylclomipramine, a metabolite that inhibits reuptake of norepinephrine, was not detectable in plasma after either CMI dose. These results support the hypothesis that serotonin is involved in the regulation of PRL, cortisol, and ACTH in humans.


This article has been cited by other articles:


Home page
 Eur Heart JHome page
G.N. Theodorakis, E.G. Livanis, D. Leftheriotis, P. Flevari, M. Markianos, and D.Th. Kremastinos
Head-up tilt test with clomipramine challenge in vasovagal syndrome--a new tilt testing protocol
Eur. Heart J., April 1, 2003; 24(7): 658 - 663.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. N. Theodorakis, M. Markianos, E. Zarvalis, E. G. Livanis, P. Flevari, and D. T. Kremastinos
Provocation of neurocardiogenic syncope by clomipramine administration during the head-up tilt test in vasovagal syndrome
J. Am. Coll. Cardiol., July 1, 2000; 36(1): 174 - 178.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
P.J. Cowen and P.A. Sargent
Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission
J Psychopharmacol, January 1, 1997; 11(4): 345 - 348.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
H. K. Manji, J. K. Hsiao, E. D. Risby, O. T. Osman, M. V. Rudorfer, and W. Z. Potter
ECT treatment does not enhance neuroendocrine responses to serotonergic challenge
J Psychopharmacol, January 1, 1992; 6(4): 501 - 508.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society